Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00ARM
|
|||
| Former ID |
DNC000353
|
|||
| Drug Name |
Brominide tartrate
|
|||
| Synonyms |
BRIMONIDINE TARTRATE; 70359-46-5; Brimonidine tartarate; Alphagan; Brimonidine D-tartrate; UNII-4S9CL2DY2H; Brimonidinne tartrate; C11H10BrN5.C4H6O6; Brimonidine L-Tartrate; Brimonidine (tartrate); Brimonidine D-tartarate; 79570-19-7; 4S9CL2DY2H; 5-Bromo-N-(4,5-dihydro-1H-imidazol-2-yl)quinoxalin-6-amine (2R,3R)-2,3-dihydroxysuccinate; UK-14304-18; Qoliana; brimonidine Purite; Brimonidine tartrate [USAN]
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2], [3] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H16BrN5O6
|
|||
| Canonical SMILES |
C1CN=C(N1)NC2=C(C3=NC=CN=C3C=C2)Br.C(C(C(=O)O)O)(C(=O)O)O
|
|||
| InChI |
1S/C11H10BrN5.C4H6O6/c12-9-7(17-11-15-5-6-16-11)1-2-8-10(9)14-4-3-13-8;5-1(3(7)8)2(6)4(9)10/h1-4H,5-6H2,(H2,15,16,17);1-2,5-6H,(H,7,8)(H,9,10)/t;1-,2-/m.1/s1
|
|||
| InChIKey |
QZHBYNSSDLTCRG-LREBCSMRSA-N
|
|||
| CAS Number |
CAS 70359-46-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7849138, 8183627, 14905997, 34718405, 50065215, 51045984, 57313614, 104304833, 117557172, 117673112, 126584763, 126668204, 126728626, 134339799, 135013414, 135258577, 162189560, 162256841, 163696689, 164194981, 172440139, 175268248, 175612226, 180185124, 184547885, 189562742, 219401610, 223400661, 223434903, 223679409, 226613279, 249865443, 250170418, 252071066, 252160248, 252215057, 252346815, 252346816
|
|||
| ADReCS Drug ID | BADD_D00295 | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Adrenergic receptor Alpha-2 (ADRA2) | Target Info | Agonist | [1], [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Alpha(2A)-adrenoceptor: G(alphai1) protein-mediated pertussis toxin-resistant attenuation of G(s) coupling to the cyclic AMP pathway. Biochem Pharmacol. 2000 Jun 15;59(12):1531-8. | |||
| REF 2 | Potent alpha(2A)-adrenoceptor-mediated vasoconstriction by brimonidine in porcine ciliary arteries. Invest Ophthalmol Vis Sci. 2001 Aug;42(9):2049-55. | |||
| REF 3 | Brimonidine. A review of its pharmacological properties and clinical potential in the management of open-angle glaucoma and ocular hypertension. Drugs Aging. 1998 Mar;12(3):225-41. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.